Friday, January 30, 2015 2:18:32 AM
Sanofi and MannKind's ultra rapid-acting inhaled-insulin Afrezza for type 1 and type 2 diabetes is now available in some US pharmacies! Though Sanofi has not officially announced its availability, Afrezza can now be picked up at retail outlets like CVS and Walgreens – we’d note that a special pharmacy order may be required, meaning you can pick it ~1-2 days after you turn the prescription in.
From speaking with pharmacists, it seems that Afrezza’s cash price costs are comparable to those of Novolog and Humalog insulin pens; it’s still unclear how much patients with insurance will need to pay for Afrezza. Given Sanofi’s expertise in selling insulin, we assume pricing will be patient-friendly.
We’ve been monitoring the twitter feed of Sam Finta (@afrezzauser), a type 1 patient who took part in Afrezza’s clinical trials and participated in the FDA Advisory Committee hearing for Afrezza, to hear his experience in these early days. The word so far is certainly very positive and we expect the product’s ease of use will appeal to doctors and nurses too. Afrezza could be an especially good option for type 2 patients that are not achieving their goals on pills, as well as any patient that dislikes injections, those struggling to manage mealtime blood sugars, and those who experience lots of hypoglycemia after meals. The inhaled insulin only comes in two sizes right now, equivalent to 4- or 8-units of injected rapid-acting insulin; it will be interesting to see how it is used in type 1. [Some may choose to use it for particularly high carb meals or to correct a very high blood sugar.] For more on Afrezza, please see our coverage of its FDA approval and partnership with Sanofi.
Kelly Close is on the scene covering the Afrezza news, check out this video below of Sam Finta using Afrezza!
http://diatribe.org/ultra-rapid-acting-inhaled-insulin-afrezza-now-available-some-us-pharmacies
Recent MNKD News
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 05/22/2024 01:00:31 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 05/22/2024 01:00:25 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 05/22/2024 01:00:19 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 05/22/2024 01:00:13 AM
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 05/21/2024 08:09:54 PM
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 05/21/2024 08:07:43 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 05/18/2024 01:36:29 AM
Avant Technologies Engages Wired4Tech to Evaluate the Performance of Next Generation AI Server Technology • AVAI • May 23, 2024 8:00 AM
Branded Legacy, Inc. Unveils Collaboration with Celebrity Tattoo Artist Kat Tat for New Tattoo Aftercare Product • BLEG • May 22, 2024 8:30 AM
"Defo's Morning Briefing" Set to Debut for "GreenliteTV" • GRNL • May 21, 2024 2:28 PM
North Bay Resources Announces 50/50 JV at Fran Gold Project, British Columbia; Initiates NI 43-101 Resources Estimate and Bulk Sample • NBRI • May 21, 2024 9:07 AM
Greenlite Ventures Inks Deal to Acquire No Limit Technology • GRNL • May 17, 2024 3:00 PM
Music Licensing, Inc. (OTC: SONG) Subsidiary Pro Music Rights Secures Final Judgment of $114,081.30 USD, Demonstrating Strength of Licensing Agreements • SONGD • May 17, 2024 11:00 AM